ABSTRACT
OBJECTIVE: To estabolish a quantitative analysis method for pharmacokinetics and bioavailability of Puerarin self-microemulsion in Beagle dogs. METHODS: A crossover design was use to detect the pharmacokinetic parameters of Puerarin self-microemulsion and suspension in Beagle dogs. The concentration of Puerarin in plasma was determined with HPLC, the pharmacokinetics parameters and bioavailability was calculated with DAS 2. 1. 1 programs. RESULTS: T(max) of Puerarin self-microemulsion and suspension were 3.0 h and 2.0 h, C(max) were 2.14 mg/L and 1.061 mg/L, AUC(0-24) were 10.642 mg h/L and 3 mg x h/L, respectively. The bioavailability of Puerarin self-microemulsion relative to Puerarin suspension were 354.73%. CONCLUSION: Puerarin self-microemulsion can significantly improve the bioavailability in Beagle dogs.
